UK-based healthcare AI company Huma has raised $80 million in Series D funding, bringing its total funding to over $300 million.
Huma has developed a modular platform that is used in over 3,000 hospitals and clinics, with over 35 million screened users and over 4 million registered users in healthcare, and has supported over 800 studies, supporting approximately 1 million participants across studies.
Huma’s technology empowers:
- A range of virtual care tools, from digital-first screening and population health initiatives to large-scale remote patient monitoring (RPM)
- Companion app to support patients through treatment and medication
- Digital clinical trials, including decentralized trials, to accelerate medical research
The company is actively involved in major national healthcare projects around the world, from the US and UK to Germany, Greece and Saudi Arabia, and works with most major pharmaceutical companies.
In conjunction with its Series D, Huma is also announcing the launch of the Huma Cloud Platform, a technology ecosystem designed to not only support the company’s digital health initiatives, but also to help other companies efficiently launch and scale their projects, aiming to reduce the time it takes to develop and launch large-scale digital health projects from years to days.
In 2023, Huma achieved the groundbreaking milestone of becoming the first and only disease-agnostic, configurable FDA Class II, EuMDR Class IIb, and Saudi Arabia FDA Class C platform that enables rapid, code-free configuration with the ability to host AI/ML models. This regulatory status significantly reduces the cost, time, and risk of delivering digital health projects through the Huma Cloud Platform.
Huma is now offering this platform, complete with a software development kit (SDK), to its customers to accelerate the development of similar applications or to incorporate the functionality into their existing solutions.
Participation in Series D included new and existing strategic and financial investors, including AstraZeneca, HAT SGR’s HAT Technology Fund 4, Hitachi Ventures’ HV Fund and Bayer Leap.
“Huma is a game changer,” said Dan Vadat, Founder and CEO of Huma.
“We aim to accelerate the adoption of digital and AI in care and research, and we will achieve this by making it easier to build digital health solutions for care and research.
We like to think of the Huma Cloud Platform as Shopify for digital health, not e-commerce. We believe that as digital and AI scale, they will become more affordable for the poor and the rich. They will help drive consistency and move healthcare from reactive to proactive.”
Huma has partnered with Google and others to develop new AI models that enable its cloud platform users to care for many times more patients with less effort, such as “10x Nurse,” which significantly reduces administrative tasks and automates the patient verification process with human intervention.
Going forward, the combination of the Huma Cloud Platform and next-generation AI models will enable Huma to drive greater impact through digital-first care and research efforts, while also helping small startups and large enterprises launch the digital solutions they need.
